Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer

Abstract

Quantitative real time PCR was performed on genomic DNA from 40 primary oral carcinomas and the normal adjacent tissues. The target genes ECGFB, DIA1, BIK, and PDGFB and the microsatellite markers D22S274 and D22S277, mapped on 22q13, were selected according to our previous loss of heterozygosity findings in head and neck tumors. Quantitative PCR relies on the comparison of the amount of product generated from a target gene and that generated from a disomic reference gene (GAPDH-housekeeping gene). Reactions have been performed with normal control in triplicates, using the 7700 Sequence Detection System (PE Applied Biosystems). Losses in the sequences D22S274 (22q13.31) and in the DIA1 (22q13.2–13.31) gene were detected in 10 out of 40 cases (25%) each. Statistically significant correlations were observed for patients with relative copy number loss of the marker D22S274 and stages T3–T4 of disease (P=0.025), family history of cancer (P=0.001), and death (P=0.021). Relative copy number loss involving the DIA1 gene was correlated to family history of cancer (P<0.001), death (P=0.002), and consumption of alcohol (P=0.026). Log-rank test revealed a significant decrease in survival (P=0.0018) for patients with DIA1 gene loss. Relative copy number losses detected in these sequences may be related to disease progression and a worse prognosis in patients with oral cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • AJCC. 1998 American Joint Committee on Cancer Cancer Staging Handbook, AJCC cancer staging manual 5th edn GB Lippincott-Raven (ed)

  • Bérgamo NA, Rogatto SR, Poli-Frederico RC, Reis PP, Kowalski LP, Zielenska M, Squire JA . 2000 Cancer Genet. Cytogenet. 119: 48–55

  • Bièche I, Olivi M, Champème M-H, Vidaud D, Lidereau R, Vidaud M . 1998 Int. J. Cancer 78: 661–666

  • Biegel JA, Fogrelgen B, Wainwright LM, Zhou JY, Bevan H, Rorke LB . 2000 Genes Chromosomes Cancer 28: 31–37

  • Blancato JK . 1999 In The principles of clinical cytogenetics Steven L Gersen and Martha B Keagle (eds) New Jersey: Humana Press pp 443–471

    Book  Google Scholar 

  • Bockmühl U, Wolf G, Schmidt S, Schwendel A, Jahnke V, Dietel M, Petersen I . 1998 Head Neck 20: 145–154

  • Boyd JM, Gallo GL, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RL . 1995 Oncogene 11: 1921–1928

  • Bryan E, Thomas NA, Palmer K, Dawson E, Englefield P, Campbell IG . 2000 Int. J. Cancer 87: 798–802

  • Bustin SA . 2000 J. Mol. Endocrinol. 25: 169–193

  • Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF . 1999 Gastroenterol. 117: 831–837

  • Cortesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, Valente G, Comoglio PM, Di Renzo MF . 2000 Int. J. Cancer 89: 286–292

  • Dracopoli NC . 2000 Current Protocols in Human Genetics New York: John Wiley and Sons

    Google Scholar 

  • Englefield P, Foulkes WD, Campbell IG . 1994 Br. J. Cancer 70: 905–907

  • Goff LK, Neat MJ, Crawley CR, Jones L, Jones E, Lister TA, Gupta RK . 2000 Br. J. Haematol. 111: 618–625

  • Grati FR, Sirchia AM, Garagiola I, Sironi E, Galioto S, Rossella F, Serafini P, Dulcetti F, Bozzetti A, Brusati R, Simoni G . 2000 Cancer Genet. Cytogenet. 118: 57–61

  • Hagiwara K, Stenman G, Honda H, Sahlin P, Andersson A, Miyazono K, Heldin CH, Ishikawa F, Takaku F . 1991 Mol. Cell Biol. 11: 2125–2132

  • Helenius MA, Saramaki OR, Linja MJ, Tammela TL, Visakorpi T . 2001 Cancer Res. 61: 5340–5344

  • Josephs SF, Ratner L, Clarke MF, Westin EH, Reitz MS, Wong-Staal F . 1984 Science 225: 636–639

  • Kim N-G, Kim JJ, Ahn J-Y, Seong C-M, Noh SH, Kim CB, Min JS, Kim H . 2000 Int. J. Cancer 85: 633–638

  • Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M . 2000 Genes Chromosomes Cancer 27: 244–251

  • Lehmann U, Glöckner S, Kleeberger W, Feist H, Von Wasielewski R, Kreipe H . 2000 Am. J. Pathol. 156: 1855–1864

  • Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ . 2000 Cancer Res. 60: 6878–6881

  • Loeb KR, Loeb LA . 2000 Carcinogenesis 21: 379–385

  • Miyakawa A, Wang X-L, Nakanishi H, Imai FL, Shiiba M, Miya T, Imai Y, Tanzawa H . 1998 Int. J. Oncol. 13: 705–709

  • Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, Robison JG, Metcalf JS, Palesch YY, Zhang Z, Gillanders WE, Cole DJ . 2001 Int. J. Cancer 93: 162–171

  • Nakanishi H, Kodera Y, Yamamura Y, Ito S, Kato T, Ezaki T, Tatematsu M . 2000 Int. J. Cancer (Pred. Oncol.) 89: 411–417

  • Oskam NT, Bijleveld EH, Hulsebos TJM . 2000 Int. J. Cancer 85: 336–339

  • Peter M, Gilbert E, Delattre O . 2001 Lab. Invest. 81: 905–912

  • Poli-Frederico RC, Bérgamo NA, Reis PP, Kowalski LP, Zielenska M, Squire JA, Rogatto SR . 2000 Head Neck 22: 585–590

  • Quon H, Liu FF, Cummings BJ . 2001 Head Neck 23: 147–159

  • Reis PP, Poli-Frederico RC, Santos RM, Nishimoto IN, Kowalski LP, Rogatto SR . 2002 Med. Sci. Monit. 8: BR89–BR94

  • Renan MJ . 1993 Mol. Carcinogenesis 7: 139–146

  • Rogatto SR, Rainho CA, Zhang ZM, Figueiredo F, Barbieri-Neto J, Georgetto SM, Squire JA . 1999 Cancer Genet. Cytogenet. 110: 23–27

  • Ruiz-Ponte C, Loidi L, Vega A, Carracedo A, Barros F . 2000 Clin. Chem. 46: 1574–1582

  • Shin E, Fujita S, Takami K, Kurahashi H, Kurita Y, Kobayashi T, Mori T, Nishisho I, Takai S . 1993 Jpn. J. Cancer Res. 84: 402–408

  • Simpson DAC, Feeney S, Boyle C, Stitt AW . 2000 Mol. Vision 6: 178–183

  • Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G, Grisar T, Igout A, Heinen E . 1999 J. Biotecnol. 75: 291–295

  • Twist EC, Ruttledge MH, Rousseau M . 1995 Hum. Mol. Genet. 3: 147–151

  • Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T . 1999 Cancer Res. 59: 5995–5998

  • Vokes EE, Weichselbaum RR, Lippman SM, Hong WK . 1993 N. Engl. J. Med. 328: 184–194

  • Wight AJ, Ogden GR . 1998 Oral Oncol. 34: 441–447

  • World Health Organization. 1990 International classification of diseases for oncology 2nd edn Geneva: World Health Organization

Download references

Acknowledgements

We would like to thank Ben Beheshti for the informatics assistance, and to Dr Juan A Rey (Madrid, Spain) and Dr Maria Zielenska (Toronto, ON, Canada) for supplying the pEFZ31 and the BAC RPI222E13 clones, respectively. The authors acknowledge FAPESP and CNPq for financial support and the Conacher Cancer Research Fund of the University Health Network, Toronto, Ontario, Canada.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Silvia R Rogatto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reis, P., Rogatto, S., Kowalski, L. et al. Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene 21, 6480–6487 (2002). https://doi.org/10.1038/sj.onc.1205864

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205864

Keywords

This article is cited by

Search

Quick links